Literature DB >> 26087135

Comparative Effectiveness Trial for Diabetic Macular Edema: Three Comparisons for the Price of 1 Study From the Diabetic Retinopathy Clinical Research Network.

Lee M Jampol1, Adam R Glassman2, Neil M Bressler3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26087135      PMCID： PMC5567804          DOI： 10.1001/jamaophthalmol.2015.1880

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN： 2168-6165            Impact factor:   7.389


× No keyword cloud information.
  7 in total

1.  Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.

Authors:  Michael J Elman; Lloyd Paul Aiello; Roy W Beck; Neil M Bressler; Susan B Bressler; Allison R Edwards; Frederick L Ferris; Scott M Friedman; Adam R Glassman; Kellee M Miller; Ingrid U Scott; Cynthia R Stockdale; Jennifer K Sun
Journal:  Ophthalmology       Date:  2010-04-28       Impact factor: 12.079

2.  Prevalence of and risk factors for diabetic macular edema in the United States.

Authors:  Rohit Varma; Neil M Bressler; Quan V Doan; Michelle Gleeson; Mark Danese; Julie K Bower; Elizabeth Selvin; Chantal Dolan; Jennifer Fine; Shoshana Colman; Adam Turpcu
Journal:  JAMA Ophthalmol       Date:  2014-11       Impact factor: 7.389

3.  Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results.

Authors:  Michael J Elman; Allison Ayala; Neil M Bressler; David Browning; Christina J Flaxel; Adam R Glassman; Lee M Jampol; Thomas W Stone
Journal:  Ophthalmology       Date:  2014-10-28       Impact factor: 12.079

4.  Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.

Authors:  John A Wells; Adam R Glassman; Allison R Ayala; Lee M Jampol; Lloyd Paul Aiello; Andrew N Antoszyk; Bambi Arnold-Bush; Carl W Baker; Neil M Bressler; David J Browning; Michael J Elman; Frederick L Ferris; Scott M Friedman; Michele Melia; Dante J Pieramici; Jennifer K Sun; Roy W Beck
Journal:  N Engl J Med       Date:  2015-02-18       Impact factor: 91.245

5.  Visual acuity as an outcome measure in clinical trials of retinal diseases.

Authors:  Roy W Beck; Maureen G Maguire; Neil M Bressler; Adam R Glassman; Anne S Lindblad; Frederick L Ferris
Journal:  Ophthalmology       Date:  2007-10       Impact factor: 12.079

6.  Revolution to a new standard treatment of diabetic macular edema.

Authors:  Lee M Jampol; Neil M Bressler; Adam R Glassman
Journal:  JAMA       Date:  2014-06-11       Impact factor: 56.272

7.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

Authors:  L P Aiello; R L Avery; P G Arrigg; B A Keyt; H D Jampel; S T Shah; L R Pasquale; H Thieme; M A Iwamoto; J E Park
Journal:  N Engl J Med       Date:  1994-12-01       Impact factor: 91.245
  7 in total
  5 in total

1.  Setting Priorities for Diabetic Retinopathy Clinical Research and Identifying Evidence Gaps.

Authors:  Jimmy T Le; Susan Hutfless; Tianjing Li; Neil M Bressler; James Heyward; Ava K Bittner; Adam Glassman; Kay Dickersin
Journal:  Ophthalmol Retina       Date:  2017 Mar-Apr

2.  Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.

Authors:  John A Wells; Adam R Glassman; Allison R Ayala; Lee M Jampol; Neil M Bressler; Susan B Bressler; Alexander J Brucker; Frederick L Ferris; G Robert Hampton; Chirag Jhaveri; Michele Melia; Roy W Beck
Journal:  Ophthalmology       Date:  2016-02-27       Impact factor: 12.079

3.  Enface Thickness Mapping and Reflectance Imaging of Retinal Layers in Diabetic Retinopathy.

Authors:  Andrew W Francis; Justin Wanek; Jennifer I Lim; Mahnaz Shahidi
Journal:  PLoS One       Date:  2015-12-23       Impact factor: 3.240

4.  Anti-Vascular Endothelial Growth Factor Comparative Effectiveness Trial for Diabetic Macular Edema: Additional Efficacy Post Hoc Analyses of a Randomized Clinical Trial.

Authors:  Lee M Jampol; Adam R Glassman; Neil M Bressler; John A Wells; Allison R Ayala
Journal:  JAMA Ophthalmol       Date:  2016-12-01       Impact factor: 7.389

5.  Visual/anatomical outcome of diabetic macular edema patients lost to follow-up for more than 1 year.

Authors:  Ji Soo Kim; Seungheon Lee; Jin Young Kim; Eoi Jong Seo; Ju Byung Chae; Dong Yoon Kim
Journal:  Sci Rep       Date:  2021-09-15       Impact factor: 4.379
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.